Vigil Neuroscience’s (VIGL) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a report published on Thursday,Benzinga reports. They currently have a $17.00 price target on the stock.

A number of other analysts have also issued reports on the company. Wedbush boosted their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. Finally, William Blair started coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $19.75.

Vigil Neuroscience Price Performance

Vigil Neuroscience stock opened at $2.35 on Thursday. The company’s 50-day moving average is $2.12 and its 200 day moving average is $3.12. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.08. On average, equities research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current year.

Institutional Trading of Vigil Neuroscience

A number of hedge funds have recently modified their holdings of VIGL. Renaissance Technologies LLC raised its position in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after acquiring an additional 11,536 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vigil Neuroscience in the 2nd quarter valued at $87,000. Geode Capital Management LLC increased its stake in Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after acquiring an additional 66,712 shares during the last quarter. Walleye Capital LLC lifted its stake in Vigil Neuroscience by 334.4% in the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after acquiring an additional 115,000 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.